AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…
Masitinib
Recommended Posts
- Starting a home bakery looks different with multiple sclerosis
- Lifestyle factors may reduce or fuel inflammation in early MS, study says
- Pain, sleep, stress linked to fatigue severity in relapsing-remitting MS
- Study links MS to greater long-term memory loss over time
- With multiple sclerosis, you don’t get to choose the ladder you climb